The Defence Minister of Russia, Sergei Shoigu, said on 27 November 2020 that Russia plans to vaccinate over 400,000 military personnel against COVID-19, as authorities reported a record 27,543 new COVID-19 cases, Reuters news agency reported on Friday.
News agencies cited Shoigu as saying that 2,500 military personnel had been vaccinated against COVID-19 already, with the total expected to reach 80,000 by the end of the year.
Russia, which is working on several vaccines against COVID-19, has reportedly seen a surge in COVID-19 infections since September 2020 but authorities have resisted imposing lockdowns, relying instead on targeted measures in certain regions.
Indian pharmaceutical company Hetero will manufacture over 100 million doses of Russia's Sputnik V COVID-19 vaccine per year under the terms of a deal with Russia's RDIF sovereign wealth fund, which was unveiled on Friday.
Siberia's Vector Institute, developing EpiVacCorona, Russia's second COVID-19 vaccine, is ready to produce up to five million doses of its vaccine per year, Alexander Ryzhikov, head of the institute's zoonotic infections and influenza department, said on Friday.
Russia, with 2,215,533 COVID-19 infections, has the fourth-largest number of COVID-19 cases in the world behind the US, India and Brazil. It has recorded 38,558 deaths related to COVID-19 since the start of the pandemic.
GSK wins European Commission approval for Shingrix prefilled syringe
Sanofi agrees USD2.2bn acquisition of Dynavax to strengthen adult vaccine portfolio
ECO Animal Health Group secures EU approval for ECOVAXXIN MS
Anixa Biosciences transfers breast cancer vaccine IND from Cleveland Clinic
Sanofi completes acquisition of Vicebio to expand respiratory vaccines portfolio
Yuyu Pharma invests in Dalan Animal Health
Avetra unveils site-centric CRO operating model
Valneva reports positive final Phase 2 results for Lyme disease vaccine VLA15
Lunai Bioworks receives first LOI to license next-generation immune cell therapy
BioNet receives positive opinion from EMA for VacPertagen marketing authorisation in EU
Anixa Biosciences secures U.S. Patent strengthening breast cancer vaccine IP into mid 2040s
PharmaJet® and EVA Pharma Partner to Scale Needle-free Polio Immunisation Across Egypt